CMS HASCHE SIGLE

Comment: This highly recommended pharma practice is well anchored in pharma advertising litigation, as seen in its work in precedent proceedings on advertising statements included in prescribing information and its advice on the new controversial topic of reimbursement advertising. Furthermore, the team headed by Wagner is still giving extensive advice on product liability. A further pillar is made up of R&D contracts, where CMS advises companies such as Bayer. With an internal partner appointment, the firm is strategically setting itself up for the industry’s next big topic: e-health. Following the recent liberalization in the market in favor of medical marijuana in Germany, CMS has already received instructions on market entry from respective producers. Competitors praise the firm in particular for its advice to clients in “international contexts”. However, market observers do not yet perceive CMS as having a particularly pronounced profile in advice on the Social Security Code (fifth book), a field which, however, a younger partner is currently developing.
Strengths: Very experienced in pharma advertising cases.
Recommended: Dr. Jens Wagner (“our man when it comes to first-rate pharma projects”, client), Prof. Dr. Matthias Eck.
Practice: All-round advice and litigation for original manufacturers of pharmaceuticals and medical products, incl. on pharma advertising, medical product law and ?patents, as well as business ?compliance. Defense against parallel imports and product forgeries, product liability. Also transaction work ( ?M&A). Advice to biotech companies, esp. in Stuttgart and Berlin. (13 partners, 3 counsel, 15 associates)
Clients: ?? Bayer on licensing and R&D agreements; DePuy International on product recall; all-round advice to Boehringer on pharma advertising; all-round advice to Elanco on pharma and unfair competition; Eli Lilly on product piracy and parallel imports; Viratherapeutics on research cooperation; mail-order pharmacy on remote treatment ban; medical cannabis producer on market entry.
  • Teilen